Media
Press Releases
HDT Bio, NCI to Co-Develop saRNA Vaccines to Prevent and Treat Multiple Cancers
The company’s saRNA vaccine technology, using its proprietary LION™ delivery system, already has proved successful in development of COVID-19 vaccines SEATTLE, WA (August 23, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases,...
HDT Bio Awarded $1.8M U.S. Army Grant to Develop Antiviral Nasal Spray to Protect Military Personnel from a Broad Spectrum of Deadly Viruses
The antiviral product, HDT-201, will utilize company’s RNA/LION™ platform technology and ultimately will be available to the public. SEATTLE, WA (August 8, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today it...
HDT Bio Awarded $1.5M Phase 2 NIH SBIR Grant to Develop RNA Vaccines and Therapeutics for Enterovirus D68, a Respiratory Virus Causing Severe Neurological Conditions in Children
SEATTLE, WA (July 20, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been awarded a nearly $1.5M Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and...
HDT Bio’s COVID-19 Vaccine Wins Regulatory Approval in India
Next-generation RNA technology can be safer, more effective at lower doses than current mRNA COVID-19 vaccines. Proprietary LION™ delivery system provides stability at refrigerator temperature SEATTLE--(June 29, 2022) -- Indian regulators have issued an Emergency Use...
HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Important for Preventing Transmission
HDT Bio’s technology uses self-replicating RNA and has the potential to deliver a COVID-19 vaccine targeting multiple variants, providing broad protection from disease and reduced transmission from breakthrough infections Seattle, WA, (April 5, 2022) – HDT Bio Corp.,...
HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next Generation COVID-19 Variant RNA Vaccine
HDT’s technology offers simpler manufacturing, easier deployment, and requires much lower doses than existing COVID-19 RNA vaccines, enabling global supply. Vaccine targets Beta variant; has demonstrated effectiveness against other variants; will be evaluated as...
Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 Trial of HDT Bio’s RNA COVID-19 Vaccine
HDT Bio’s RNA-based vaccine offers simpler manufacturing, easier deployment without the need for ultra-low freezers, and requires vastly lower dosing than current RNA COVID-19 vaccines SEATTLE & SALVADOR, Brazil--January 17, 2022--HDT Bio Corp., a U.S. developer...
HDT Bio Partner Quratis Doses First Healthy Volunteers in Phase 1 Trial of HDT Bio’s RNA COVID-19 Vaccine in South Korea
HDT’s RNA-based vaccine offers simpler manufacturing, greater stability, and vastly lower effective dosing than current mRNA COVID-19 vaccines Quratis could make vaccine available across East Asia Seattle, WA, and Seoul, KOREA (December 13, 2021) – HDT Bio Corp., a...
HDT Bio Partners with Brazil’s SENAI CIMATEC to Advance RNA COVID-19 Vaccine to Fight Pandemic
Agreement extends HDT Bio’s international COVID 19 vaccine partnerships as part of its long-term goal of changing the global-health paradigm to address global-health inequity The company’s RNA-based vaccine offers simpler manufacturing, easier deployment without the...
In the News
Bioprocess Online: Navigating Cancer Vaccines’ Regulatory Waters
Click here to view article
Bioprocess Online Live: Shelf Lives & Logistics: Ensuring The Stability Of Therapeutic Cancer Vaccines
Click here to view article
Bioprocess Online: Shelf Lives & Logistics: Ensuring The Stability Of Therapeutic Cancer Vaccines
Click here to view article
Bioprocess Online Live: Manufacturing Challenges In Cancer Vaccine Development
Click here to view article
Bioprocess Online: Manufacturing Challenges In Cancer Vaccine Development
Click here to view article
Bioprocess Online Live: Maintaining Cost Efficiency In A Personalized Oncology World
Click here to view article
Bioprocess Online: Maintaining Cost Efficiency In A Personalized Oncology World
Click here to view article
Bioprocess Online Live: Personalized Or Off The Shelf? Differentiated Approaches To Cancer Vaccines
Click here to view article
Bioprocess Online: Personalized Or Off The Shelf? Differentiated Approaches To Cancer Vaccines
Click here to view article
Bioprocess Online Live: What Makes A Good Therapeutic Cancer Vaccine Antigen?
Click here to view article